• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Digital Turbine, Inc. - Common Stock
Noble Mineral Exploration Inc
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.975 +0.185 (+2.37%)
Delayed Quote Updated: 11:33 AM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 725,888
Open 7.770
Bid (Size) 7.970 (2,700)
Ask (Size) 7.980 (3,600)
Prev. Close 7.790
Today's Range 7.770 - 8.005
52wk Range 6.230 - 11.22
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioCryst Eyes $1B Rare-Disease Future Through External Innovation ↗
September 18, 2026
BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief... 
Via MarketBeat
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
September 06, 2026
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds

Performance

52-Week Range 28.9% below 52-week high
7.975
6.2352W Low 11.2252W High
1 Week 6.7% below 1-week high
7.741W Low 8.551W High

BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) traded between $6.23 and $11.22 over the past 52 weeks and last traded at $7.97, 28.9% below its 52-week high. Over the past week it ranged between $7.74 and $8.55.

Past 12 Months
-4.6%
-8.1%
-12.5%
-13.2%
+6.3%
+15.1%
1W -$0.38
1M -$0.71
3M -$1.13
6M -$1.21
YTD +$0.47
1Y +$1.04

BCRX was +15.1% over the past year, -13.2% over six months, +6.3% year to date, -4.6% in the last week.

12 Months vs Market
BCRX
+15.1%
DIA
+11.4%
SPY
+14.7%
QQQ
+18.3%
IWM
+9.7%

Over the past 12 months BCRX returned +15.1% versus DIA (Dow) +11.4%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +9.7%.

Volume & Liquidity 0.18× 3-mo avg
Today 725,888 3-mo avg 4.1M
1W
4.2M
1M
5.3M
3M
4.1M
6M
4.6M
YTD
4.9M
1Y
4.7M

BCRX most recently traded 725,888 shares against a 3-month average daily volume of 4.1M.

More News

Read More
BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
August 21, 2026
Via Chartmill
News headline image
BioCryst (BCRX) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) Surges on Q2 Earnings Beat ↗
August 05, 2026
Via Chartmill
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss ↗
May 06, 2026
Via Chartmill
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗
February 26, 2026
Via Chartmill
News headline image
BioCryst Pharmaceuticals Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings
News headline image
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
July 15, 2026
From BioCryst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
June 29, 2026
From BioCryst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances ↗
June 06, 2026
Via MarketBeat
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
December 12, 2025
Via Stocktwits
News headline image
Earnings Scheduled For November 3, 2025 ↗
November 03, 2025
Via Benzinga
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗
October 14, 2025
Via Stocktwits
News headline image
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings ↗
May 07, 2026
Via Benzinga
News headline image
BioCryst (BCRX) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
November 21, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 12, 2025
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗
November 03, 2025
Via The Motley Fool
Topics Earnings
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
November 03, 2025
Via Benzinga
News headline image
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗
November 03, 2025
Via Chartmill
Topics Earnings
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
October 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
October 21, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
October 16, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
October 14, 2025
Via Benzinga

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?
BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market
What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?
The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 7.975
When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 10/19/26 11:33 AM ET
What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.48B
How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?
BioCryst Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap